Polaris Genomics
Polaris Genomics is a biotech company dedicated to mapping the biological underpinnings of mental health and neuropsychiatric conditions through AI-powered genomics. They develop objective diagnostics and therapeutics, focusing on conditions like PTSD, depression, anxiety, ADHD, TBI, and substance use disorder. Their platform, the ADAPT Neuropsychiatric Biomarker Discovery Platform™, analyzes blood sample biomarkers to support drug development and clinical tools, aiming to reduce stigma, improve diagnosis, and enable personalized treatment. They actively collaborate with researchers, pharma, military, and academic institutions to advance mental health care.
Industries
Nr. of Employees
small (1-50)
Polaris Genomics
9841 Washingtonian Blvd., Suite 200, Gaithersburg, MD 20878, USA
Products
Targeted neuropsychiatric biomarker discovery platform
An integrated platform combining a targeted RNA transcript panel, analytics engine, and centralized data repository to define RNA expression profiles correlated with neuropsychiatric conditions and treatment response from blood samples.
Genomics-based PTSD screening blood test
A blood-based test that measures RNA expression levels of genomic markers correlated with stress-response dysregulation to screen and triage individuals for PTSD risk.
Targeted neuropsychiatric biomarker discovery platform
An integrated platform combining a targeted RNA transcript panel, analytics engine, and centralized data repository to define RNA expression profiles correlated with neuropsychiatric conditions and treatment response from blood samples.
Genomics-based PTSD screening blood test
A blood-based test that measures RNA expression levels of genomic markers correlated with stress-response dysregulation to screen and triage individuals for PTSD risk.
Services
Discovery of neuropsychiatric biomarker signatures using targeted transcript panels, NGS, and machine learning to support research and diagnostic assay development.
Design and execution of analytical and clinical validation studies for genomics-based diagnostics intended for screening and triage in neuropsychiatric conditions.
Provision of bioinformatics pipelines, machine learning model development, and statistical analysis for large-scale genomic and phenotypic datasets.
Laboratory sequencing and multi-omic processing workflows for research studies, including sample preparation, sequencing, and primary data generation.
RT-qPCR-based molecular testing workflows for surveillance applications, including pooled saliva testing and rapid reporting.
Strategic partnerships with pharmaceutical companies, academic institutions, defense organizations, and health systems to run translational studies and validation projects.
Discovery of neuropsychiatric biomarker signatures using targeted transcript panels, NGS, and machine learning to support research and diagnostic assay development.
Design and execution of analytical and clinical validation studies for genomics-based diagnostics intended for screening and triage in neuropsychiatric conditions.
Provision of bioinformatics pipelines, machine learning model development, and statistical analysis for large-scale genomic and phenotypic datasets.
Laboratory sequencing and multi-omic processing workflows for research studies, including sample preparation, sequencing, and primary data generation.
RT-qPCR-based molecular testing workflows for surveillance applications, including pooled saliva testing and rapid reporting.
Strategic partnerships with pharmaceutical companies, academic institutions, defense organizations, and health systems to run translational studies and validation projects.
Expertise Areas
- Biomarker discovery and translational genomics
- Transcriptomics and targeted RNA assay development
- Bioinformatics and machine learning for genomics
- Clinical diagnostic development and validation
Key Technologies
- Next-generation sequencing (NGS)
- RNA sequencing (RNA-Seq)
- Targeted RNA transcript panels
- RT-qPCR and pooled-sample testing
News & Updates
Dr. Anne Naclerio discusses the future of TBI care driven by biomarker research at Polaris Genomics.
Exploration of biomarkers' potential in diagnosing and treating mild traumatic brain injury, especially in military and sports populations.
Insights into traumatic brain injury and the potential of biomarkers for better diagnosis and treatment.
Dr. Anne Naclerio discusses the future of TBI care driven by biomarker research at Polaris Genomics.
Exploration of biomarkers' potential in diagnosing and treating mild traumatic brain injury, especially in military and sports populations.
Insights into traumatic brain injury and the potential of biomarkers for better diagnosis and treatment.